Loading...
OTCM
MTEM
Market cap0kUSD
Mar 12, Last price  
0.00USD
1D
-99.80%
1Q
-100.00%
Jan 2017
-100.00%
IPO
-100.00%
Name

Molecular Templates Inc

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
0.00
EPS
—
Div Yield, %
—
Shrs. gr., 5y
17.93%
Rev. gr., 5y
51.07%
Revenues
57m
+190.10%
0690,0001,461,0001,436,0001,440,0001,440,000062,0005,867,00012,495,00014,722,00076,915,0001,880,0002,408,0007,283,00019,499,00015,635,00038,697,00019,754,00057,306,000
Net income
-8m
L-91.24%
-23,566,000-44,408,000-55,686,000-30,664,000-18,292,000-23,648,000-18,682,000-25,653,000-71,135,000-28,415,000-21,584,00043,822,000-24,094,000-23,140,000-30,287,000-69,537,000-104,916,000-79,314,000-92,718,000-8,124,000
CFO
-42m
L-53.02%
-10,800,000-29,879,000-46,424,000-29,245,000-16,308,000-17,785,000-22,384,000-23,851,00029,913,00010,151,000-27,735,000-38,003,000-25,099,000-14,264,000-4,465,000-25,244,000-83,797,000-30,387,000-89,024,000-41,820,000
Earnings
Mar 27, 2025

Profile

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
URL
https://mtem.com/
IPO date
Feb 04, 2005
Employees
111
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
57,306
190.10%
19,754
-48.95%
Cost of revenue
74,683
116,425
Unusual Expense (Income)
NOPBT
(17,377)
(96,671)
NOPBT Margin
Operating Taxes
(11)
53
Tax Rate
NOPAT
(17,366)
(96,724)
Net income
(8,124)
-91.24%
(92,718)
16.90%
Dividends
Dividend yield
Proceeds from repurchase of equity
18,383
33
BB yield
Debt
Debt current
2,488
2,182
Long-term debt
21,972
60,630
Deferred revenue
5,904
Other long-term liabilities
4,108
1,295
Net debt
11,622
(726)
Cash flow
Cash from operating activities
(41,820)
(89,024)
CAPEX
(200)
(3,198)
Cash from investing activities
29,095
95,317
Cash from financing activities
(9,116)
(265)
FCF
(8,156)
(94,571)
Balance
Cash
11,523
61,049
Long term investments
1,315
2,489
Excess cash
9,973
62,550
Stockholders' equity
(452,887)
(444,778)
Invested Capital
473,437
487,426
ROIC
ROCE
EV
Common stock shares outstanding
4,501
3,756
Price
Market cap
EV
EBITDA
(10,732)
(89,288)
EV/EBITDA
Interest
2,654
4,782
Interest/NOPBT